Targeting TBK1 pharmacologically or by mRNA knockdown induces apoptosis and reduces cell viability in a subset of acute myeloid leukemia (AML) cells with an activated MYC signaling pathway necessary for survival (63). Here, TBK1 is linked to acute myeloid leukemia.